Latest HAE analysis boosts BioCryst shares

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) jumped $1.60 (31%) to $6.73 after it said a second interim analysis showed two of three doses of BCX7353 significantly reduced hereditary angioedema attacks vs. placebo in the Phase II APeX-1 trial. The candidate is a second-generation kallikrein inhibitor.

BioCryst’s pre-specified, per-protocol analysis evaluated pooled data from 44 patients in the first two parts of the three-part trial. Once-daily 125 mg and 350 mg oral BCX7353 reduced mean HAE attacks during weeks two through four by 73% (p=0.002) and 58% (p=0.001), respectively, compared to placebo. The study's 250 mg middle dose led to a 37% reduction, which was not significant (p=0.128). A separate analysis of the study's intent-to-treat population also showed that the low and high doses led to significant reductions, while the middle dose did not...